Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Google Secures Pentagon AI Deal for Classified Projects 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
South Korean biotech company Celltrion Inc. plans to merge with its two affiliates, Celltrion Healthcare Co. and Celltrion Pharma Inc., to establish a holding company structure by the end of 2021.
Celltrion Group Chairman Seo Jung-jin would establish Celltrion Healthcare Holdings by investing his stakes in Celltrion Healthcare, making the holding company its largest shareholder.
Celltrion Group Chairman Seo Jung-Jin would hold 11.21 percent in Celltrion Healthcare Holdings, which in turn would have a 24.33 percent stake.
The process would be hastened when requirements for relevant laws regarding anti-monopoly and fair trade are met.
Seo noted that the merger would depend upon the wishes of shareholders.
Celltrion is conducting phase one clinical trials on patients of its coronavirus treatment, CT-P59, to evaluate the safety and efficacy of the treatment.
